# A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

> **NCT00150267** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 976 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Xalacom

## Key facts

- **NCT ID:** NCT00150267
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 976 (ACTUAL)
- **Last updated:** 2008-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00150267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00150267, "A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00150267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*